Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool

Launched by REGINA ELENA CANCER INSTITUTE · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how urine tests can help detect bladder cancer early. The researchers are looking at specific changes in the DNA found in urine, known as methylation patterns, to see if they can identify bladder cancer before it becomes more serious. The goal is to validate existing tests and explore new methods to improve early diagnosis and predict how the disease may progress.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of bladder cancer. Healthy volunteers are also welcome, as long as they do not have a history of bladder cancer or certain other medical conditions. Participants will undergo tests and procedures as part of the study, and everyone will need to provide written consent to join. By taking part, you may help researchers find better ways to diagnose and understand bladder cancer, potentially improving outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient group
• • age ≥ 18 years
• • proven diagnosis of bladder cancer (infiltrating muscle or non-infiltrating muscle)
• • performance status (PS) 0-1
• • ability to follow the procedures established by the study
• • written consent for participation in the study and data processing
• • group of healthy subjects
• • age ≥ 18 years
• • ability to follow the procedures established by the study
• • written consent for participation in the study and data processing
• Exclusion Criteria:
• • Patient group
• • presence of metastatic bladder cancer
• • lack of autonomy in following the procedures established by the study
• • group of healthy subjects
• • previous or current clinical history associated with bladder cancer
• • diagnostic suspicion associated with tumor pathologies
• • ongoing or previous systemic oncological treatments
• • presence of inflammatory and/or autoimmune diseases related to particular conditions potentially modifying the methylation profile
• • existing pharmacological treatments (and/or any other type of treatment) that could alter the results of the analyzes conducted for the present study
• • lack of autonomy in following the procedures established by the study